Julian Harrison
Stock Analyst at BTIG
(4.58)
# 191
Out of 5,174 analysts
106
Total ratings
57.14%
Success rate
21.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Reiterates: Buy | $40 | $13.45 | +197.40% | 3 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $137 | $73.00 | +87.67% | 6 | Mar 23, 2026 | |
| TBPH Theravance Biopharma | Reiterates: Buy | $21 | $14.90 | +40.94% | 6 | Mar 20, 2026 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $42.22 | +65.80% | 6 | Mar 16, 2026 | |
| JBIO Jade Biosciences | Maintains: Buy | $28 → $39 | $13.26 | +194.12% | 2 | Mar 16, 2026 | |
| ORKA Oruka Therapeutics | Reiterates: Buy | $73 | $39.90 | +82.96% | 5 | Mar 13, 2026 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $46 | $49.00 | -6.12% | 5 | Mar 9, 2026 | |
| LQDA Liquidia | Maintains: Buy | $49 → $50 | $35.20 | +42.05% | 7 | Mar 5, 2026 | |
| INVA Innoviva | Reiterates: Buy | $35 | $21.92 | +59.67% | 2 | Feb 26, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $4 | $1.36 | +194.12% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $110.17 | +36.15% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $30 | $16.71 | +79.53% | 5 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $5.35 | +217.76% | 3 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $151 | $72.96 | +106.96% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1 | $0.34 | +197.62% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.69 | +85.87% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $13.64 | +178.59% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.07 | +624.88% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.13 | +219.49% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $27.19 | +124.35% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $100.39 | -18.32% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $6.68 | +19.76% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $3.36 | +346.43% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.99 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $63.02 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.20 | +4,443.16% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.30 | +142.42% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.60 | +1,223.19% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.61 | +24,490.16% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $531.82 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $40
Current: $13.45
Upside: +197.40%
Apogee Therapeutics
Mar 23, 2026
Reiterates: Buy
Price Target: $137
Current: $73.00
Upside: +87.67%
Theravance Biopharma
Mar 20, 2026
Reiterates: Buy
Price Target: $21
Current: $14.90
Upside: +40.94%
Spyre Therapeutics
Mar 16, 2026
Reiterates: Buy
Price Target: $70
Current: $42.22
Upside: +65.80%
Jade Biosciences
Mar 16, 2026
Maintains: Buy
Price Target: $28 → $39
Current: $13.26
Upside: +194.12%
Oruka Therapeutics
Mar 13, 2026
Reiterates: Buy
Price Target: $73
Current: $39.90
Upside: +82.96%
Maze Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $46
Current: $49.00
Upside: -6.12%
Liquidia
Mar 5, 2026
Maintains: Buy
Price Target: $49 → $50
Current: $35.20
Upside: +42.05%
Innoviva
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $21.92
Upside: +59.67%
Akebia Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $1.36
Upside: +194.12%
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $110.17
Upside: +36.15%
Feb 23, 2026
Maintains: Buy
Price Target: $24 → $30
Current: $16.71
Upside: +79.53%
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $5.35
Upside: +217.76%
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $72.96
Upside: +106.96%
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.34
Upside: +197.62%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $2.69
Upside: +85.87%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $13.64
Upside: +178.59%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.07
Upside: +624.88%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.13
Upside: +219.49%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $27.19
Upside: +124.35%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $100.39
Upside: -18.32%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $6.68
Upside: +19.76%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $3.36
Upside: +346.43%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.99
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $63.02
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.20
Upside: +4,443.16%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.30
Upside: +142.42%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.60
Upside: +1,223.19%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.61
Upside: +24,490.16%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $531.82
Upside: -